Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease
Federica Piani(Medical University of Graz), Petter Bjornstad(University of Colorado Denver), Leif Erik Lovblom(Mount Sinai Hospital), Josephine Tse(University Health Network), David Z.I. Cherney(University Health Network), Isabella Melena(Children's Hospital Colorado), Leslie Cham(University Health Network), Vesta Lai(University Health Network), Yuliya Lytvyn(University Health Network), Bruce A. Perkins(Sinai Health System), Andrej Orszag(University of Toronto), Trenton Reinicke(Harvard University)
Cited by 11
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
|American Journal of Physiology-Renal Physiology|2014|173